{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:15Z","timestamp":1790668515831,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01265-4","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:12:43Z","timestamp":1785262363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Sorbitol as a Pharmaceutical Excipient in Oral Liquid Pediatric Formulations Submitted to the U.S. FDA"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-6378","authenticated-orcid":false,"given":"Gelareh A.","family":"Abulwerdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-4288","authenticated-orcid":false,"given":"Brianna","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-2029","authenticated-orcid":false,"given":"Susan","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-4230","authenticated-orcid":false,"given":"Elimika Pfuma","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-9301","authenticated-orcid":false,"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"4","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1208\/s12248-013-9509-z","volume":"15","author":"ML Chen","year":"2013","unstructured":"Chen ML, Sadrieh N, Yu L. Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. AAPS J. 2013;15(4):1043\u201350.","journal-title":"AAPS J"},{"issue":"9","key":"1265_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/03639045.2019.1640722","volume":"45","author":"RP Dash","year":"2019","unstructured":"Dash RP, Srinivas NR, Babu RJ. Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability. Drug Dev Ind Pharm. 2019;45(9):1421\u20139.","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"1265_CR3","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1021\/acs.molpharmaceut.4c01309","volume":"22","author":"K Matsui","year":"2025","unstructured":"Matsui K. Biopharmaceutics aspects of sugar alcohols: implementation of patient-centricity in pharmaceutical development and clinical use. Mol Pharm. 2025;22(4):1775\u201389.","journal-title":"Mol Pharm"},{"key":"1265_CR4","unstructured":"US Food and Drug Administration Consumer Magazine: Sulfanilamide Diaster. 1981. Issue:[Available from: https:\/\/www.fda.gov\/files\/about%20fda\/published\/The-Sulfanilamide-Disaster.pdf. Accessed 23 Jan 2026."},{"key":"1265_CR5","unstructured":"US Food and Drug Administration. Promoting safe and effective drugs for 100 years. Available from: FDA Consumer magazine [Available from: https:\/\/www.fda.gov\/files\/Promoting-Safe-and-Effective-Drugs-for-100-Years-%28download%29.pdf. Accessed 23 Jan 2026."},{"key":"1265_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010119","author":"M Bobillot","year":"2024","unstructured":"Bobillot M, Delannoy V, Trouillard A, Kinowski JM, Sanchez-Ballester NM, Soulairol I. Potentially harmful excipients: state of the art for oral liquid forms used in neonatology and pediatrics units. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16010119.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1265_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11095-006-9120-4","volume":"24","author":"ML Chen","year":"2007","unstructured":"Chen ML, Straughn AB, Sadrieh N, Meyer M, Faustino PJ, Ciavarella AB, et al. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res. 2007;24(1):73\u201380.","journal-title":"Pharm Res"},{"issue":"3","key":"1265_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/cpt.943","volume":"103","author":"K Adkison","year":"2018","unstructured":"Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label. Randomized Study Clin Pharmacol Ther. 2018;103(3):402\u20138.","journal-title":"Randomized Study Clin Pharmacol Ther"},{"issue":"2","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2011.225","volume":"91","author":"P Kasirye","year":"2012","unstructured":"Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther. 2012;91(2):272\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1265_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3851\/IMP1931","volume":"16","author":"K Chokephaibulkit","year":"2011","unstructured":"Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, et al. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine\/lamivudine\/nevirapine in HIV-infected children. Antivir Ther. 2011;16(8):1287\u201395.","journal-title":"Antivir Ther"},{"issue":"10","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/INF.0b013e3181e2189d","volume":"29","author":"N Vanprapar","year":"2010","unstructured":"Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, et al. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J. 2010;29(10):940\u20134.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"1265_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/cpt.1147","volume":"104","author":"SY Choi","year":"2018","unstructured":"Choi SY, Viswanathan P, Sherwat A, Seo SK. Effects of sorbitol on the pharmacokinetics of lamivudine solution and the FDA\u2019s decision to increase the dose of lamivudine solution for pediatric patients. Clin Pharmacol Ther. 2018;104(5):785\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1265_CR13","unstructured":"Inter-Agency Agreement between the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the U.S. Food and Drug Administration (FDA) final report [Available from: https:\/\/www.nichd.nih.gov\/sites\/default\/files\/inline-files\/Formulations_Platform_Report2.pdf. Accessed 23 Jan 2026."},{"key":"1265_CR14","unstructured":"Norwegian Institute of Public Health ATC\/DDD Index 2026 [Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 23 Jan 2026."},{"key":"1265_CR15","doi-asserted-by":"publisher","unstructured":"Pharmacopeia US. NF Monographs, Sorbitol 2020 [Available from: https:\/\/doi.org\/10.31003\/USPNF_M77640_04_01.","DOI":"10.31003\/USPNF_M77640_04_01"},{"key":"1265_CR16","doi-asserted-by":"publisher","unstructured":"Pharmacopeia US. USP Monographs NF Monographs, Sorbitol Solution. 2020. [Available from: https:\/\/doi.org\/10.31003\/USPNF_M77670_04_01.","DOI":"10.31003\/USPNF_M77670_04_01"},{"key":"1265_CR17","doi-asserted-by":"publisher","unstructured":"Pharmacopeia US. NF Monographs, Sorbitol Sorbitan Solution. .2020. [Available from: https:\/\/doi.org\/10.31003\/USPNF_M77672_02_01.","DOI":"10.31003\/USPNF_M77672_02_01"},{"issue":"2 Suppl","key":"1265_CR18","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1067\/mpd.2003.25","volume":"142","author":"L Hendeles","year":"2003","unstructured":"Hendeles L. Selecting a systemic corticosteroid for acute asthma in young children. J Pediatr. 2003;142(2 Suppl):S40-4.","journal-title":"J Pediatr"},{"key":"1265_CR19","unstructured":"Rowe RCS, PJ, Quinn ME. Handbook of pharmaceutical excipients. Sixth ed: Pharmaceutical Press; 2009."},{"issue":"6","key":"1265_CR20","doi-asserted-by":"publisher","first-page":"e1600","DOI":"10.1542\/peds.2011-0993","volume":"128","author":"DI Rappaport","year":"2011","unstructured":"Rappaport DI, Collins B, Koster A, Mercado A, Greenspan J, Lawless S, et al. Implementing medication reconciliation in outpatient pediatrics. Pediatrics. 2011;128(6):e1600\u20137.","journal-title":"Pediatrics"},{"key":"1265_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/children11070821","author":"A Zanin","year":"2024","unstructured":"Zanin A, Baratiri F, Roverato B, Mengato D, Pivato L, Avagnina I, et al. Polypharmacy in children with medical complexity: a cross-sectional study in a pediatric palliative care center. Children. 2024. https:\/\/doi.org\/10.3390\/children11070821.","journal-title":"Children"},{"issue":"8","key":"1265_CR22","first-page":"557","volume":"65","author":"S Liauw","year":"2019","unstructured":"Liauw S, Saibil F. Sorbitol: often forgotten cause of osmotic diarrhea. Can Fam Physician. 2019;65(8):557\u20138.","journal-title":"Can Fam Physician"},{"key":"1265_CR23","unstructured":"US Food and Drug Administration. Inactive ingredient search for approved drug products [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm. Accessed 23 Jan 2026."},{"key":"1265_CR24","unstructured":"European Medicines Agency. Information for the package leaflet regarding fructose and sorbitol used as excipients in medicinal products for human use 2017 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/information-package-leaflet-regarding-fructose-and-sorbitol-used-excipients-medicinal-products-human-use_en.pdf. Accessed 23 Jan 2026."},{"issue":"4","key":"1265_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4212\/cjhp.v73i4.3023","volume":"73","author":"C Litalien","year":"2020","unstructured":"Litalien C, Autmizguine J, Carli A, Giroux D, Lebel D, Leclerc JM, et al. Providing suitable pediatric formulations for Canadian children: a call for action. Can J Hosp Pharm. 2020;73(4):247\u201356.","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"1265_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.xphs.2020.05.013","volume":"110","author":"M Yamane","year":"2021","unstructured":"Yamane M, Matsui K, Sugihara M, Tokunaga Y. The provisional no-effect threshold of sugar alcohols on oral drug absorption estimated by physiologically based biopharmaceutics model. J Pharm Sci. 2021;110(1):467\u201377.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1265_CR27","doi-asserted-by":"publisher","first-page":"F236","DOI":"10.1136\/adc.2008.146035","volume":"94","author":"A Whittaker","year":"2009","unstructured":"Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(4):F236\u201340.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"6","key":"1265_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00431-012-1872-8","volume":"172","author":"C Tuleu","year":"2013","unstructured":"Tuleu C, Breitkreutz J. Educational paper: formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr. 2013;172(6):717\u201320.","journal-title":"Eur J Pediatr"},{"key":"1265_CR29","doi-asserted-by":"publisher","DOI":"10.7363\/070112","author":"L Cuzzolin","year":"2018","unstructured":"Cuzzolin L. Neonates exposed to excipients: concern about safety. J Pediatr Neonatal Individual Med. 2018. https:\/\/doi.org\/10.7363\/070112.","journal-title":"J Pediatr Neonatal Individual Med"},{"key":"1265_CR30","unstructured":"US Food and Drug Administration. Pediatric information incorporated into human prescription drug and biological product labeling guidance for industry. 2019. [Available from: https:\/\/www.fda.gov\/media\/84949\/download. Accessed 23 Jan 2026."},{"key":"1265_CR31","unstructured":"US Food and Drug Administration label for mesna injectable [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/019884s016,020855s003lbl.pdf. Accessed 23 Jan 2026."},{"key":"1265_CR32","unstructured":"US Food and Drug Administration label for sodium ferric gluconate complex in sucrose injection [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020955s020lbl.pdf. Accessed 23 Jan 2026."},{"key":"1265_CR33","unstructured":"US Food and Drug Administration label for deflazacort oral suspension [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208684s006,208685s007lbl.pdf. Accessed 23 Jan 2026."},{"issue":"1","key":"1265_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2013.08.078","volume":"457","author":"MA Turner","year":"2013","unstructured":"Turner MA, Duncan J, Shah U, Metsvaht T, Varendi H, Nellis G, et al. European study of neonatal exposure to excipients: an update. Int J Pharm. 2013;457(1):357\u20138.","journal-title":"Int J Pharm"},{"issue":"3","key":"1265_CR35","first-page":"175","volume":"25","author":"RS Meyers","year":"2020","unstructured":"Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, et al. Key potentially inappropriate drugs in pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175\u201391.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"1265_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","volume":"457","author":"S Salunke","year":"2013","unstructured":"Salunke S, Brandys B, Giacoia G, Tuleu C. The STEP (safety and toxicity of excipients for paediatrics) database: Part 2 - the pilot version. Int J Pharm. 2013;457(1):310\u201322.","journal-title":"Int J Pharm"},{"key":"1265_CR37","unstructured":"US Food and Drug Administration. Guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients. 2005. [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-studies-safety-evaluation-pharmaceutical-excipients. Accessed 23 Jan 2026."},{"key":"1265_CR38","unstructured":"US Food and Drug Administration. Guidance for industry: M9 biopharmaceutics classification system based biowaivers. 2021. [Available from: https:\/\/www.fda.gov\/media\/148472\/download. Accessed 23 Jan 2026."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01265-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:41Z","timestamp":1790665361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01265-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01265-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The opinions expressed in this article are those of the authors and should not be interpreted as the position of the US Food and Drug Administration.","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"124"}}